# US 2010/0166825 A1 · Treating and/or preventing urinary incontinence using prodrugs of gaba analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166825 A1
- Document ID: US20100166825A1
- Status: Published application
- Kind: A1
- Application number: 12/720,414
- Filed: 2010-03-09
- Published: 2010-07-01
- Earliest claimed: 2003-09-11
- Assignees: XenoPort, Inc.
- Inventors: Ronald W. Barrett
- Web page: https://patentgrep.com/patent/US20100166825A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/195: having an amino group
- A61P 13/10: of the bladder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.

## Claims

### Claim 1

A method of treating or preventing urinary incontinence in a patient in need of such treatment or prevention comprising administering to the patient a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

### Claim 2

A method of treating or preventing urinary incontinence in a patient in need of such treatment or prevention comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a prodrug of a GABA analog, or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the GABA analog is gabapentin or pregabalin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the GABA analog is administered in an amount of between about 10 mg and about 5000 mg per day.

### Claim 5 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the patient is a female patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein the female patient is postmenopausal.

### Claim 7 (depends on 6)

The method of claim 6, wherein menopause is drug induced or surgically induced.

### Claim 8 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the patient is a male patient.

### Claim 9 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the urinary incontinence is drug-induced.

### Claim 10 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the prodrug is administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, instillationally, intracavitarally or intravesical instillationally, intraocularly, intraarteriall, intralesionally, by implantation or by application to mucous membranes.

### Claim 11 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the prodrug is administered orally.

### Claim 12 (depends on 1, 2)

The method of claim 1 or claim 2, comprising administering the prodrug in a sustained release oral dosage form.

### Claim 13 (depends on 12)

The method of claim 12, wherein the dosage form releases the prodrug gradually over a period of at least about 6 hours after swallowing the dosage form, thereby providing a therapeutic concentration of a GABA analog in the plasma of the patient.

### Claim 14 (depends on 12)

The method of claim 12, wherein the dosage form is an osmotic dosage form, a prodrug-releasing polymer, a prodrug-releasing lipid, a prodrug-releasing wax, tiny timed-release pills or prodrug releasing beads.

### Claim 15 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the prodrug of a GABA analog has the structure of Formula (I):
or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
n is 0 or 1;
Y is O or S;
R16 is hydrogen, alkyl or substituted alkyl;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R2 and R16 together with the atoms to which they are attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R3 and R6 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R4 and R5 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R4 and R5 together with the carbon atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl or bridged cycloalkyl ring;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;
R13 and R14 are each independently hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R13 and R14 together with the carbon atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring; and
R25 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl.

### Claim 16 (depends on 15)

The method of claim 15, wherein the prodrug of a GABA analog has the structure of Formulae (II) or (III):

### Claim 17 (depends on 16)

The method of claim 16, wherein n is 0.

### Claim 18 (depends on 16)

The method of claim 16, wherein n is 1, R16 is hydrogen and R2 is selected from the group consisting of hydrogen, methyl, 2-propyl, 2-butyl, isobutyl, tert-butyl, cyclopentyl, cyclohexyl, phenyl, benzyl, 4-hydroxybenzyl, 4-imidazolylmethyl, 3-indolylmethyl, —CH2OH, —CH(OH)CH3, —CH2CO2H, —CH2CH2CO2H, —CH2CONH2, —CH2CH2CONH2, —CH2CH2SCH3, —CH2SH, —CH2(CH2)3NH2 and —CH2CH2CH2NHC(NH)NH2.

### Claim 19 (depends on 17)

The method of claim 17, wherein R25 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and sec-butyl, R13 is methyl and R14 is hydrogen.

### Claim 20 (depends on 17)

The method of claim 17, wherein R25 is isopropyl, R13 is methyl and R14 is hydrogen.

### Claim 21

A pharmaceutical composition for treating a patient suffering from urinary incontinence comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.

### Claim 22

A pharmaceutical composition suitable for preventing urinary incontinence in a patient at risk of urinary incontinence comprising a therapeutically effective amount of a prodrug of a GABA analog or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.

### Claim 23 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the urinary incontinence is characterized by symptoms of urge incontinence.

### Claim 24 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the urinary incontinence is characterized by symptoms of stress incontinence.
